08/28/2026
A recent federal criminal case should have the attention of the RUO peptide industry.
In USA v. Brandon Piper, a Michigan case resulting in a 21-month prison sentence, the government focused on the sale and marketing of semaglutide, tirzepatide, retatrutide, and the use of RUO/NFHC labeling alongside conduct indicating products were intended for human use.
In this article, Jeff Cohen breaks down the details of the case and what they reveal about the government’s increasing scrutiny of RUO peptide businesses—from website claims and affiliate programs to product sourcing, testing, labeling, and customer communications.
For companies operating in the RUO space, this case offers an important look at where regulatory risk can cross into criminal exposure.
Credit: Jeff Cohen
👉 Read the full article - floridahealthcarelawfirm.com/michigan-criminal-case-is-important-for-ruo-peptide-compan